Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer
June 4th 2022
Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers
June 2nd 2022
Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022
May 27th 2022
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022
May 4th 2022
Immutep Presents New and Significant Data from the AIPAC Study
April 29th 2022
Immutep Quarterly Activities Report
April 28th 2022
Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting
March 30th 2022
Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients
March 24th 2022
Immutep Announces Publication of TACTI-002 Abstract at ESMO’s European Lung Cancer Congress 2022
March 18th 2022
Immutep to Present Biomarker and Multivariate Analysis from Phase IIb AIPAC Study in Metastatic Breast Cancer at ESMO’s Breast Cancer Congress 2022
March 18th 2022
Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525
March 10th 2022
Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast Cancer
February 25th 2022
Immutep Appoints Lucy Turnbull as Non-Executive Director
February 24th 2022
Immutep to Present at Healthcare Investor Conferences
February 18th 2022
Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022
February 11th 2022
Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor
January 31st 2022
Immutep to Present at February Investor Conferences
January 25th 2022
Immutep Quarterly Activities Report
We use cookies and other tracking technologies to improve your browsing experience on our website, to analyze our website traffic, and to understand where our visitors are coming from. By browsing our website, you consent to our use of cookies and other tracking technologies. To learn more about cookies view ourPrivacy policy